Graphy Inc., a Seoul-based photopolymer maker, has signed an initial KRW 2 billion ($1.3m) supply agreement with South Korean dental implant maker MegaGen Implant Co., Ltd. The deal covers Tera Harz E-Namel, a light-curing, high-ceramic-content resin aimed at long-term dental crowns, along with 3D printers, nitrogen curing units and resin removal equipment.
South Korea’s Ministry of Food and Drug Safety has already cleared the resin. Graphy is still pursuing FDA clearance and CE marking, so the material isn’t commercially available in the US or EU yet.
MegaGen chairman Park Kwang Bum said the resin showed shorter production times and lighter restorations than conventional zirconia workflows across roughly 50 clinical cases, though no hard numbers on time savings or weight reduction were given. Graphy chairman Un-Seob Sim called the agreement the start of a “commercial partnership” focused on building repeat orders from dental practices and labs, rather than a one-off sale.
The two companies are separately in late-stage talks on an annual supply deal for cone-beam CT systems from Ray Co., Ltd., in which Graphy holds a 26.14% stake. The stated goal is a “K-Dental Workflow” linking CBCT diagnostics, MegaGen’s implant treatment and Graphy’s 3D-printed restorations into one pipeline, sold as a bundle to clinics outside Korea.
This is a first commercial order, not a volume contract: $1.3 million buys an initial batch of resin and hardware, and whether it scales depends on uptake Graphy hasn’t disclosed figures for yet. No pricing per unit, no production capacity, and no timeline for the CBCT agreement or for FDA/CE clearance have been published.